A detailed history of Pacer Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Pacer Advisors, Inc. holds 1,038 shares of CRSP stock, worth $48,775. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,038
Previous 538 92.94%
Holding current value
$48,775
Previous $36,000 55.56%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$51.17 - $68.18 $25,585 - $34,090
500 Added 92.94%
1,038 $56,000
Q1 2024

May 10, 2024

BUY
$60.67 - $89.12 $32,640 - $47,946
538 New
538 $36,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.67B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.